FRISS launches Insurance Is A Beautiful Thing campaign
1.9.2020 09:00:00 EEST | Business Wire | Press release
FRISS, the leading provider of AI-powered fraud and risk solutions for P&C insurance companies, known for its creative approach toward the insurance industry, launched an international campaign to regain a feeling of pride in the insurance industry. “Because insurance is anything but boring,” says FRISS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005336/en/
Jeroen Morrenhof, CEO and Co-founder of FRISS: “We often recognize that people take insurance for granted. We want to remind everyone how important our industry is. The most incredible things in life can only be achieved thanks to insurance. Therefore we believe insurance really is a beautiful thing. And the world should know that, too.”
With its AI-powered fraud detection and risk assessment software, FRISS helps insurers provide a faster and more seamless experience for their customers. Morrenhof concludes: “I hope Insurance is a beautiful thing helps people grasp the beauty of our industry, and makes them realize how times continuously evolve, trends develop and customer expectations change. Carriers should change with them. It's time to find new ways of doing business. This is our wake-up call for insurers: Now is the time for digital transformation.”
According to research from the Insurance Information Institute, barely half of those surveyed have a positive perception of the insurance industry.
Yoram Elzas, Head of Creative at FRISS, says: “The lack of appreciation for the insurance industry is exactly why we are launching this campaign. We are putting the emotion back into insurance. Think of what brings you joy, personally. Without the right coverage, no one would be able to travel around the world, drive a car or buy their own house. And companies would never be able to hire staff, innovate or expand. Insurance allows us to take risks. Everyone in our industry should be proud of that.”
Insurance is a beautiful thing launched today. Feel the emotion and share the story: https://youtu.be/EqwKT11uEgo.
About FRISS
FRISS is a fast-growing insurtech with 100% focus on automated fraud detection and risk assessment for P&C insurance companies worldwide. Their AI-powered software solutions for underwriting, claims and special investigation units help 175+ insurers grow their business sustainably. Insurers go live within 4 months, realize up to 10 times ROI and see an 80% increase in straight-through processing of policy applications and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth and improve the overall customer experience. For more information, visit www.friss.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005336/en/
Contact information
FRISS PR & Communications
Ruud van Gerwen
Head of Global Marketing
ruud.van.gerwen@friss.com
+31 30 767 0352
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 12:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key Takeaways What Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-source project — now adopted by 1,500+ data teams, with 1.1M + monthly downloads, and a ~4,000-member community. In 2024, it launched Elementary Cloud which added enterprise-grade capabilities on t
Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom